NCT01436747View on ClinicalTrials.gov

Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

July 31, 2015

Conditions
Disorder of Transplanted KidneyProteinuriaAlbuminuria
Interventions
DRUG

Paricalcitol

2 micrograms daily, peroral, 24 weeks

DRUG

Placebo

2 micrograms daily, peroral, 24 weeks

Trial Locations (1)

1000

University Medical Centre Ljubljana, Ljubljana

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University Medical Centre Ljubljana

OTHER

NCT01436747 - Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter